Publications

24

Jun, 2016

Optimal timing of antiretroviral treatment initiation in HIV-positive children and adolescents – a multiregion analysis from Southern Africa, West Africa, and Europe.

 

Authors: Schomaker M, Leroy V, Wolfs T, Technau KG, Renner L, Judd A, et al. on behalf of the IeDEA West and Southern Africa regional collaborations and COHERE in EuroCoord.

Published in: International Journal of Epidemiology – in press.

Read

1

Jun, 2016

BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial

 

Author: Butler K, Inshaw J, Ford D, et al.

Published in:  Health Technol Assess2016;20(49):1-108.

Abstract: The trial showed that short-cycle antiretroviral therapy was not inferior to continuous therapy in suppressing human immunodeficiency viral load in young people taking efavirenz-based first-line therapy and a viral load of < 50 copies/ml, with similar resistance, safety and inflammatory marker profiles.

Read

1

Jun, 2016

Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial

 

Author: The BREATHER (PENTA 16) Trial Group

Published inLancet HIV. 2016;3(9):e421-430

Abstract: For HIV-1-infected young people facing lifelong antiretroviral therapy (ART), short cycle therapy with long-acting drugs offers potential for drug-free weekends, less toxicity, and better quality-of-life. We aimed to compare short cycle therapy (5 days on, 2 days off ART) versus continuous therapy (continuous ART).

Read

15

May, 2016

The pharmacokinetics of abacavir 600 mg once daily in HIV-1-positive pregnant women

 

Authors: Schalkwijk S, Colbers A, Konopnicki D, et al.

Published in: Aids. 2016; 30(8):1239-1244

Abstract: To describe the pharmacokinetics of abacavir 600 mg once daily (q.d.) in HIV-1-positive women during pregnancy and postpartum.

27

Apr, 2016

High prevalence of herpes simplex virus (HSV)- type 2 co-infection among HIVpositive women in Ukraine, but no increased HIV mother-to-child transmission risk

 

Authors: Aebi-Popp K, Bailey H, Malyuta R, Volokha A, Thorne C.

Published in: BMC Pregnancy Childbirth. 2016;16:94.

Read

24

Apr, 2016

Neurocognition and quality of life after reinitiating antiretroviral therapy in children randomized to planned treatment interruption” has been accepted for publication in AIDS

 

Authors: Ananworanich J, Melvin D, Ramos Amador JT, Childs T, Medin G, Boscolo V, Compagnucci A, Kanjanavanit S, Montero S, Gibb DM, on behalf of the PENTA 11 study group.

Published in: AIDS: 24 April 2016 – Volume 30 – Issue 7 – p 1075–1081

Read

13

Mar, 2016

First reported use of elvitegravir and cobicistat during pregnancy

 

Authors: Schalkwijk S, Colbers A, Konopnicki D, et al.

Published in: Aids. Vol 30. England2016:807-808.

10

Mar, 2016

Children and young people with perinatal HIV in Europe: epidemiological sitation in 2014 and implications for the future

Tags:

Authors: Writing group for the Kids to Adults Working Group and Data Management and Harmonisation Group in EuroCoord.

Published in: Euro Surveill. 2016; 21: ES.201621.10.30162.

Abstract: Accurate ascertainment of the number of children living with human immunodeficiency virus (HIV) is important to plan paediatric and adolescent health services. In Europe, the first generation of perinatally HIV-infected survivors are transferring to adult care and their health needs are unknown. We undertook an online survey of HIV cohort studies participating in the EuroCoord Network of Excellence to ascertain the number of perinatally HIV-infected (pHIV) patients included, to compare it with those published by the European Centre for Disease Prevention and Control (ECDC) and the World Health Organization (WHO) and to assess the ability of countries to follow up pHIV patients after transfer to adult care. At the end of 2013, 16 countries in EuroCoord reported 8,229 pHIV patients in follow-up in cohorts, compared with 5,160 cumulative diagnoses reported by the ECDC in the same area. Follow-up of pHIV patients after transfer to adult care varied. It is likely that the number of diagnoses of perinatal HIV reported to ECDC is an underestimate, although this varies by country. Further work is needed to refine estimates and encourage follow-up in adult HIV cohorts to investigate long-term outcomes and improve the care of the next generation of children with HIV.

Read

10

Mar, 2016

Children and young people with perinatal HIV in Europe: epidemiological situation in 2014 and implications for the future.

 

Authors: Kids to Adults Working Group and Data Management and Harmonisation Group in EuroCoord.

Published in: Eurosurveillance 2016; 21(10):pii=30162.

Read

26

Feb, 2016

The European Paediatric Mycology Network (EPMyN): Towards a Better Understanding and Management of Fungal Infections in Children

 

Author: Adilia Warris

Published in: Curr Fungal Infect Rep. 2016;10:7-9.

Abstract: The European Paediatric Mycology Network (EPMyN) was launched in 2014 to create a European platform for research and education in the field of paediatric mycology. The EPMyN aims to address the lack of paediatric specific evidence and knowledge needed to (1) improve the management and outcome of invasive fungal infections in children and neonates and to (2) enhance and develop paediatric anti-fungal stewardship programmes.

This article is published with open access at Springerlink.com

Read